Recent Updates
Recently added Catalysts
TLX Positive Sentiment

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Key Takeaway: Telix is set to host a symposium at the EANM 2023 in Vienna, focusing on personalized diagnostics in urological cancers. The event will feature expert speakers, including renowned professionals from various institutions, who will discuss advancements in nuclear medicine. Attendees will have the chance to engage in discussions and enhance their understanding of oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exciting symposium with expert speakers
  • Focus on personalized diagnostics in urological cancers
  • Opportunity for knowledge enhancement in oncology
  • Engagement in innovative research and discussions

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

5 September 2023
Telix is looking forward to our next symposium at the Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria. We have an exciting line-up of expert speakers who will each present on important developments in the personalisation of diagnostics in urological cancers before opening the discussion up to the floor. Nuclear medicine is a fast-moving field, so don’t miss out on the opportunity to enhance your knowledge and discover new viewpoints in oncology.
City Vienna, Austria
Time Sunday 10th September 2023 from 13:15 – 14:45 (CEST)
Location Hall F1 – Austria Center Vienna

Speaker biographies

Prof. Stefano Fanti (Chair and Speaker) Prof. Fanti has been Associate Professor at the University of Bologna since 2006 and Full Professor since 2017. His research is focused on the field of diagnostics, particularly in Nuclear Medicine and the use of PET in oncology, with particular reference to innovative radiopharmaceuticals. Prof. Fanti is engaged in national and international research projects, collaborating with numerous institutions, including IAEA and EANM. He has authored numerous publications in his field and has received several awards and recognitions from prestigious Centers and Institutes.
Prof. Macarena Rodríguez Fraile (Speaker) Macarena Rodríguez-Fraile is a Senior Consultant in Nuclear Medicine at Clínica Universidad de Navarra, Pamplona, Spain. She defended her PhD in 2011 with the thesis entitled “Diagnostic and prognostic value of PET/CT with 18 F-FDG and 11 C-Choline in prostate carcinoma”. Her main areas of research are imaging in prostate cancer, in breast cancer, liver radioembolization and bone densitometry. She is a professor at the Faculty of Medicine of Universidad de Navarra. She is currently the president of the Oncology Group of the Spanish Society of Nuclear Medicine.
Prof. Karolien Goffin (Speaker) Prof. Dr. Karolien Goffin is a staff member of nuclear medicine at the University Hospital Leuven and associate professor at KU Leuven, Leuven, Belgium. She is part of the multidisciplinary teams dealing with uro-oncology, among others. Her main research interests are preclinical development of diagnostic and therapeutic radiopharmaceuticals, the application of existing oncological PET tracers in a broad range of malignancies and clinical settings and the introduction of novel PET tracers and therapeutic radiopharmaceuticals in (uro-)oncology. Prof. Goffin is chair of the Oncology and Theranostics Committee of EANM, board member of the Belgian Multidisciplinary meeting on Urological Cancers (BMUC) and member of the Imaging Group of the European Organization for Research and Treatment of Cancer (EORTC). She is associate editor of EJNMMI and editorial board member of JNM, Cancers and Clinical and Translational Imaging.
Dr. László Papp (Speaker) László Papp obtained his medical physics PhD at the Medical University of Vienna (MUV) in 2021, focusing on medical image analysis with artificial intelligence (AI) approaches. He is the co-fouder of Dedicaid GmbH, a spin-off of MUV, which was acquired and now wholly-owned by Telix Pharmaceuticals. Within Dedicaid, he conceptualized and implemented the AI solutions to aid the building process of cloud AI clinical decision support systems (CDSS). Before becoming a researcher at MUV, he was the head of software R&D operations at a major medical imaging company in Hungary for almost 10-years. He is currently a full-time postdoc at MUV, building his research team as the group lead of the Applied Quantum Computing (AQC) group.
What a line up – we can’t wait for you to join us in Vienna!

Frequently Asked Questions

What is the focus of the Telix symposium at EANM 2023?

The symposium will focus on personalized diagnostics in urological cancers.

When and where is the Telix symposium taking place?

It will take place on September 10, 2023, in Vienna, Austria.

Who are the speakers at the Telix symposium?

Speakers include Prof. Stefano Fanti, Prof. Macarena Rodríguez-Fraile, and others.

What topics will be discussed at the symposium?

The discussions will cover important developments in nuclear medicine and oncology.

Last updated: Sep 5, 2023